These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1096 related articles for article (PubMed ID: 15526251)
1. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat. Erman A; Veksler S; Gafter U; Boner G; Wittenberg C; van Dijk DJ J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251 [TBL] [Abstract][Full Text] [Related]
2. Effect of enalapril and losartan on the events that precede diabetic nephropathy in rats. Volpini RA; da Silva CG; Costa RS; Coimbra TM Diabetes Metab Res Rev; 2003; 19(1):43-51. PubMed ID: 12592643 [TBL] [Abstract][Full Text] [Related]
3. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients. Renke M; Tylicki L; Rutkowski P; Wojnarowski K; Lysiak-Szydlowska W; Rutkowski B Scand J Urol Nephrol; 2005; 39(6):511-7. PubMed ID: 16303729 [TBL] [Abstract][Full Text] [Related]
4. Insulin and losartan reduce proteinuria and renal hypertrophy in the pregnant diabetic rat. Natif N; Sclarovsky-Benjaminov F; Van Dijk DJ; Sulkes J; Gafter U; Boner G; Erman A J Lab Clin Med; 2003 Sep; 142(3):166-71. PubMed ID: 14532904 [TBL] [Abstract][Full Text] [Related]
5. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019 [TBL] [Abstract][Full Text] [Related]
6. Renal effects of long-term leptin infusion and preventive role of losartan treatment in rats. Gunduz Z; Dursun N; Akgun H; Ozturk F; Okur H; Koc N Regul Pept; 2005 Dec; 132(1-3):59-66. PubMed ID: 16229907 [TBL] [Abstract][Full Text] [Related]
7. Chronic salt loading and cardiovascular-associated changes in experimental diabetes in rats. Maeda C; Schaan B; Oliveira E; Oliveira V; De Angelis K; Irigoyen M Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):574-80. PubMed ID: 17581211 [TBL] [Abstract][Full Text] [Related]
8. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. Zoja C; Corna D; Gagliardini E; Conti S; Arnaboldi L; Benigni A; Remuzzi G Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975 [TBL] [Abstract][Full Text] [Related]
9. Angiotensin II inhibition attenuates postexercise proteinuria in rats. Gündüz F; Kuru O; Sentürk UK Int J Sports Med; 2005 Nov; 26(9):710-3. PubMed ID: 16237614 [TBL] [Abstract][Full Text] [Related]
10. Increased serum angiotensin-converting enzyme activity and plasma angiotensin II levels during pregnancy and postpartum in the diabetic rat. van Dijk DJ; Boner G; Giler S; Erman A J Renin Angiotensin Aldosterone Syst; 2001 Sep; 2(3):193-8. PubMed ID: 11881122 [TBL] [Abstract][Full Text] [Related]
11. Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis. Mathew R; Futterweit S; Valderrama E; Tarectecan AA; Bylander JE; Bond JS; Trachtman H Am J Physiol Renal Physiol; 2005 Oct; 289(4):F911-21. PubMed ID: 15942051 [TBL] [Abstract][Full Text] [Related]
13. [Effect of losartan and enalapril on urinary excretion of 8-isoprostane in experimental nephrotic syndrome]. Tesar V; Zima T; Jirsa M; Crkovská J; Stípek S; Vernerová Z; Seráková M Cas Lek Cesk; 1999 Oct; 138(18):560-4. PubMed ID: 10596472 [TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damage. Perico N; Amuchastegui CS; Malanchini B; Bertani T; Remuzzi G Exp Nephrol; 1994; 2(4):220-8. PubMed ID: 8069658 [TBL] [Abstract][Full Text] [Related]
15. [Molecular mechanisms of nephro-protective action of enalapril in experimental chronic renal failure]. Ciechanowicz A Ann Acad Med Stetin; 1999; Suppl 52():1-93. PubMed ID: 10589103 [TBL] [Abstract][Full Text] [Related]
16. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Weir MR Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185 [TBL] [Abstract][Full Text] [Related]
17. Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats. Kalender B; Oztürk M; Tunçdemir M; Uysal O; Dagistanli FK; Yegenaga I; Erek E Acta Histochem; 2002; 104(2):123-30. PubMed ID: 12086332 [TBL] [Abstract][Full Text] [Related]
18. Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy. Seki N; Hashimoto N; Suzuki Y; Yagui K; Saito Y Diabetes Res Clin Pract; 2006 May; 72(2):135-41. PubMed ID: 16290123 [TBL] [Abstract][Full Text] [Related]
19. Protective effects of blocking renin-angiotensin system on the progression of renal injury in glomerulosclerosis. Ji Z; Huang C; Liang C; Chen B; Chen S; Sun W Cell Mol Immunol; 2005 Apr; 2(2):150-4. PubMed ID: 16191423 [TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker. Zhu S; Liu Y; Wang L; Meng QH Nephrol Dial Transplant; 2008 Sep; 23(9):2841-6. PubMed ID: 18390891 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]